Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.745 USD | +12.98% | -9.10% | +6.39% |
04-18 | Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup | DJ |
04-18 | Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall | MT |
Sales 2024 * | 68.34M 93.41M | Sales 2025 * | 84.72M 116M | Capitalization | 734M 1B |
---|---|---|---|---|---|
Net income 2024 * | -101M -138M | Net income 2025 * | -108M -148M | EV / Sales 2024 * | 10.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.66 x |
P/E ratio 2024 * |
-5.45
x | P/E ratio 2025 * |
-5.52
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.32% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | +12.98% | ||
1 week | -9.10% | ||
Current month | -47.86% | ||
1 month | -49.03% | ||
3 months | +1.82% | ||
6 months | +96.07% | ||
Current year | +6.39% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Rabia Ozden
CTO | Chief Tech/Sci/R&D Officer | 56 | 21-01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 4.745 | +12.98% | 3,883,481 |
24-04-25 | 4.2 | -9.58% | 4,707,729 |
24-04-24 | 4.645 | -7.10% | 3,954,779 |
24-04-23 | 5 | -1.48% | 2,278,666 |
24-04-22 | 5.075 | -2.78% | 3,745,815 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.39% | 734M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- OCUL Stock